Johnson & Johnson CEO Says Eliminating Certain Cancers Within a Decade Is 'Realistic'

LONDON — Johnson & Johnson Chairman and Chief Executive Joaquin Duato told executives at the WSJ Leadership Institute CEO Summit in London that curing certain cancers within the next 10 years is a realistic scientific target, pointing to advances in immunotherapy and the company's recent acquisition of Firefly Bio as evidence that the field has already shifted. His remarks, made before a gathering of global business leaders in the British capital, signal a broader recalibration among major pharmaceutical companies away from treating cancer purely as a condition to be managed.

From Terminal Prognosis to Long-Term Remission

Duato used multiple myeloma to illustrate how sharply treatment outcomes have improved. Life expectancy for patients with the disease now stands at 10 years, against what he described as "only single years" previously. Johnson & Johnson has developed treatments that direct a patient's own immune system against cancer cells, he said, and patients who had already moved into hospice care have remained in remission for more than five years after a single administration. "That is spectacular," Duato said at the summit.

His projection for the coming decade is to "try to eliminate cancer," though he acknowledged the goal is uneven across tumour types. "It's realistic to believe that we are going to cure certain cancers, and some others we're going to turn into chronic diseases," he said.

Firefly Bio Acquisition and AI as Structural Bets

Johnson & Johnson recently acquired Firefly Bio, a biotech firm that develops drugs designed to enter cancer cells and target proteins associated with difficult-to-treat gene mutations. Duato described artificial intelligence as a "force multiplier" across J&J's healthcare operations. Fox News senior medical analyst Dr. Marc Siegel, commenting on Duato's outlook, said AI will guide increasingly targeted treatments by widening knowledge of cancer mutations, and that biomarkers combined with AI will sharpen early diagnoses and support more personalised surgical approaches.

Dementia and Longevity as the Longer Arc

Duato placed oncology within a wider thesis on science's capacity to address social problems at scale. He named dementia as the next major unmet need, and predicted that life expectancy — which has risen steadily over the past century — will continue to increase as longevity technologies advance. Johnson & Johnson's work to understand the biology of cancer growth, he said, runs in parallel with its broader ambition to improve quality of life across an ageing global population, framing long-run demographic pressure as a research driver rather than simply a commercial opportunity.